Brain Injury Associated With Widely Abused Amphetamines: Neuroinflammation, Neurogenesis And Blood-Brain Barrier

Current Drug Abuse Reviews

Volumn 3, Issue 4, 2010, Pages 239-254

  Silva, Ana P ^a   Martins, Tânia ^a   Baptista, Sofia ^a   Gonçalves, Joana ^a   Agasse, Fabienne ^b   Malva, João O ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Adult brain neurogenesis; Amphetamines; Blood brain barrier; Glial cells; Matrix metalloproteinases; Neuroinflammation; Neurotoxicity; Subgranular zone; Subventricular zone

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE DERIVATIVE; CELECOXIB; GAMMA INTERFERON; GELATINASE A; GELATINASE B; IBUPROFEN; INDOMETACIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; KETOPROFEN; METHAMPHETAMINE; MINOCYCLINE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD BRAIN BARRIER; BRAIN INJURY; CAUSAL ATTRIBUTION; CYTOKINE RESPONSE; DRUG ABUSE; DRUG DEPENDENCE; DRUG MECHANISM; HUMAN; INFLAMMATORY DISEASE; NERVOUS SYSTEM DEVELOPMENT; NEUROMODULATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 79551645771     PISSN: 18744737     EISSN: None     Source Type: Journal    
DOI: 10.2174/1874473711003040239     Document Type: Review

References (208)

1. United Nations Office on Drug and Crime. World Drug Report 2010; 1-313.
2. Tanibuchi Y, Shimagami M, Fukami G, Sekine Y, Iyo M, Hashimoto K. A case of methamphetamine use disorder treated with the antibiotic drug minocycline. Gen Hosp Psychiatry 2010; 32: 559 e1-3.
3. Potash MN, Gordon KA, Conrad KL. Persistent psychosis and medical complications after a single ingestion of MDMA ecstasy: a case report and review of the literature. Psychiatry (Edgmont) 2009; 6: 40-4.
4. Simon SL, Domier C, Carnell J, Brethen P, Rawson R, Ling W. Cognitive impairment in individuals currently using methamphetamine. Am J Addict 2000; 9: 222-31.
5. Lundqvist T. Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol Biochem Behav 2005; 81: 319-30.
6. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 2007; 47: 681-98.
7. Capela JP, Carmo H, Remião F, Bastos ML, Meisel A, Carvalho F. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol 2009; 39: 210-71.
8. Melega WP, Williams AE, Schmitz DA, DiStefano EW, Cho AK. Pharmacokinetic and pharmacodynamic analysis of the actions of D-amphetamine and D-methamphetamine on the dopamine terminal. J Pharmacol Exp Ther 1995; 274: 90-6.
9. Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005; 75: 406-33.
10. Rothman RB, Baumann MH. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 2003; 479: 23-40.
11. Yamamoto BK, Bankson MG. Amphetamine neurotoxicity: cause and consequence of oxidative stress. Crit Rev Neurobiol 2005; 17: 87-117.
12. Quinton MS, Yamamoto BK. Causes and consequences of methamphetamine and MDMA toxicity. AAPS J 2006; 8: E337-47.
13. Cunha-Oliveira T, Rego AC, Oliveira CR. Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs. Brain Res Rev 2008; 58: 192-208.
14. Yamamoto BK, Raudensky J. The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. J Neuroimmune Pharmacol 2008; 3: 203-17.
15. Krasnova IN, Cadet JL. Methamphetamine toxicity and messengers of death. Brain Res Rev 2009; 60: 379-407.
16. Yamamoto BK, Moszczynska A, Gudelsky GA. Amphetamine toxicities: classical and emerging mechanisms. Ann N Y Acad Sci 2010; 1187: 101-21.
17. Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller RJ, Westley J. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res 1980; 181: 151-60.
18. Volkow ND, Chang L, Wang GJ, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001; 158: 377-82.
19. Schenk JO. The functioning neuronal transporter for dopamine: kinetic mechanisms and effects of amphetamines, cocaine and methylphenidate. Prog. Drug Res 2002; 59: 111-31.
20. Gulley JM, Zahniser NR. Rapid regulation of dopamine transporter function by substrates, blockers and presynaptic receptor ligands. Eur J Pharmacol 2003; 479: 139-52.
21. Jayanthi LD, Ramamoorthy S. Regulation of monoamine transporters: influence of psychostimulants and therapeutic antidepressants. AAPS J 2005; 7: E728-38.
22. Liang NY, Rutledge CO. Comparison of the release of [3H]dopamine from isolated corpus striatum by amphetamine, fenfluramine and unlabelled dopamine. Biochem Pharmacol 1982; 31: 983-92.
23. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 1995; 15: 4102-8.
24. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 1998; 18: 8417-22.
25. McCann UD, Kuwabara H, Kumar A, et al. Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 2008; 62: 91-100.
26. Thompson PM, Hayashi KM, Simon SL, et al. Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 2004; 24: 6028-36.
27. Sulzer D, Maidment NT, Rayport S. Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J Neurochem 1993; 60: 527-35.
28. Stephans SE, Yamamoto BK. Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse 1994; 17: 203-9.
29. Fleckenstein AE, Hanson GR. Impact of psychostimulants on vesicular monoamine transporter function. Eur J Pharmacol 2003; 479: 283-9.
30. Thomas DM, Dowgiert J, Geddes TJ, Francescutti-Verbeem D, Liu X, Kuhn DM. Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci Lett 2004; 367: 349-54.
31. Thomas DM, Walker PD, Benjamins JA, Geddes TJ, Kuhn DM. Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther 2004; 311: 1-9.
32. Hald A, Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp Neurol 2005; 193: 279-90.
33. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Pharmacol Rev 2003; 55: 463-508.
34. Simões PF, Silva AP, Pereira FC, et al. Methamphetamine induces alterations on hippocampal NMDA and AMPA receptor subunit levels and impairs spatial working memory. Neuroscience 2007; 150: 433-41.
35. Simões PF, Silva AP, Pereira FC, et al. Methamphetamine changes NMDA and AMPA glutamate receptor subunit levels in the rat striatum and frontal cortex. Ann N Y Acad Sci 2008; 1139: 232-41.
36. Mark KA, Soghomonian JJ, Yamamoto BK. High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J Neurosci 2004; 24: 11449-56.
37. Burrows KB, Nixdorf WL, Yamamoto BK. Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines. J Pharmacol Exp Ther 2000; 292: 853-60.
38. Nixdorf WL, Burrows KB, Gudelsky GA, Yamamoto BK. Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate. J Neurochem 2001; 77: 647-54.
39. Malberg JE, Sabol KE, Seiden LS. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J Pharmacol Exp Ther 1996; 278: 258-67.
40. Fleckenstein AE, Wilkins DG, Gibb JW, Hanson GR. Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration. J Pharmacol Exp Ther 1997; 283: 281-5.
41. Nguyen MD, Julien JP, Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci 2002; 3: 216-27.
42. Farooqui A, Horrocks LA, Farooqui T. Modulation of inflammation in brain: a matter of fat. J Neurochem 2007; 101: 577-99.
43. Ghirnikar RS, Lee YL, Eng LF. Inflammation in traumatic brain injury: role of cytokines and chemokines. Neurochem Res 1998; 23: 329-40.
44. Bonifati DM, Kishore U. Role of complement in neurodegeneration and neuroinflammation. Mol Immunol 2007; 44: 999-1010.
45. Minghetti L, Levi G. Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide. Prog Neurobiol 1998; 54: 99-125.
46. Stoll G, Jander S. The role of microglia and macrophages in the pathophysiology of the CNS. Prog. Neurobiol 1999; 58: 233-47.
47. Streit WJ, Walter SA, Pennell NA. Reactive microgliosis. Prog Neurobiol 1999; 57: 563-81.
48. Boje KM, Arora PK. Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. Brain Res 1992; 587: 250-6.
49. Pekny M, Nilsson M. Astrocyte activation and reactive gliosis. Glia 2005; 50: 427-34.
50. Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci 2009; 32: 638-47.
51. Swanson RA, Ying W, Kauppinen TM. Astrocyte influences on ischemic neuronal death. Curr Mol Med 2004; 4: 193-205.
52. Bush TG, Puvanachandra N, Horner CH, et al. Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron 1999; 23: 297-308.
53. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol 2010; 119: 7-35.
54. Hamby ME, Sofroniew MV. Reactive Astrocytes as Therapeutic Targets for CNS Disorders. Neurotherapeutics 2010; 7: 494-506.
55. Drew PD, Storer PD, Xu J, Chavis JA. Hormone regulation of microglial cell activation: relevance to multiple sclerosis. Brain Res Brain Res Rev 2005; 48: 322-7.
56. Minghetti L. Role of inflammation in neurodegenerative diseases. Curr Opin Neurol 2005; 18: 315-21.
57. Pereira FC, Imam SZ, Gough B, et al. Acute changes in dopamine release and turnover in rat caudate nucleus following a single dose of methamphetamine. J Neural Transm 2002; 109: 1151-8.
58. Pereira FC, Lourenço ES, Borges F, et al. Single or multiple injections of methamphetamine increased dopamine turnover but did not decrease tyrosine hydroxylase levels or cleave caspase-3 in caudate-putamen. Synapse 2006; 1: 185-93.
59. Sattler R, Xiong Z, Lu WY, MacDonald JF, Tymianski M. Distinct roles of synaptic and extrasynaptic NMDA receptors in excitotoxicity. J Neurosci 2000; 20: 22-33.
60. Cadet JL, Krasnova IN, Jayanthi S, Lyles J. Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox Res 2007; 11: 183-202.
61. LaVoie MJ, Card JP, Hastings TG. Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp Neurol 2004; 187: 47-57.
62. Orio L, O'Shea E, Sanchez V, et al. 3,4-Methylenedioxymethamphetamine increases interleukin-1beta levels and activates microglia in rat brain: studies on the relationship with acute hyperthermia and 5-HT depletion. J Neurochem 2004; 89: 1445-53.
63. Fantegrossi WE, Ciullo JR, Wakabayashi KT, De La Garza R2nd, Traynor JR, Woods JH. A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. Neuroscience 2008; 151: 533-43.
64. Miguel-Hidalgo JJ. The role of glial cells in drug abuse. Curr Drug Abuse Rev 2009; 2: 72-82.
65. Benveniste EN, Sparacio SM, Norris JG, Grenett HE, Fuller GM. Induction and regulation of interleukin-6 gene expression in rat astrocytes. J Neuroimmunol 1990; 3: 201-12.
66. Yamaguchi T, Kuraishi Y, Minami M, Nakai S, Hirai Y, Satoh M. Methamphetamine-induced expression of interleukin-1 beta mRNA in the rat hypothalamus. Neurosci Lett 1991; 128: 90-2.
67. Gonçalves J, Martins T, Ferreira R, et al. Methamphetamineinduced early increase of IL-6 and TNF-alpha mRNA expression in the mouse brain. Ann N Y Acad Sci 2008; 1139: 103-11.
68. Sriram K, Miller DB and O'Callaghan JP. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-α. J Neurochem 2006; 96: 706-18.
69. Gonçalves J, Baptista S, Martins T, et al. Methamphetamineinduced neuroinflammation and neuronal dysfunction in the mice hippocampus: preventive effect of indomethacin. Eur J Neurosci 2010; 31: 315-26.
70. Nakajima A, Yamada K, Nagai T, et al. Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity. J Neurosci 2004; 24: 2212-25.
71. Basu A, Krady JK, Levison SW. Interleukin-1: a master regulator of neuroinflammation. J Neurosci Res 2004; 78: 151-6.
72. Numachi Y, Ohara A, Yamashita M, et al. Methamphetamineinduced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters. Eur J Pharmacol 2007; 572: 120-8.
73. Leon LR. Invited review: cytokine regulation of fever: studies using gene knockout mice. J Appl Physiol 2002; 92: 2648-55.
74. Quintanilla RA, Orellana DI, González-Billault C, Maccioni RB. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res 2004; 295: 245-57.
75. Sparkman NL, Buchanan JB, Heyen JR, Chen J, Beverly JL, Johnson RW. Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers. J Neurosci 2006; 26: 10709-16.
76. Ladenheim B, Krasnova IN, Deng X, et al. Methamphetamineinduced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6. Mol Pharmacol 2000; 58: 1247-56.
77. Penkowa M, Giralt M, Carrasco J, Hadberg H, Hidalgo J. Impaired inflammatory response and increased oxidative stress and neurodegeneration after brain injury in interleukin-6-deficient mice. Glia 2000; 32: 271-85.
78. Yamashita T, Sawamoto K, Suzuki S, et al. Blockade of interleukin-6 signaling aggravates ischemic cerebral damage in mice: possible involvement of Stat3 activation in the protection of neurons. J Neurochem 2005; 94: 459-68.
79. Hakkoum D, Stoppini L, Muller D. Interleukin-6 promotes sprouting and functional recovery in lesioned organotypic hippocampal slice cultures. J Neurochem 2007; 100: 747-57.
80. Hozumi H, Asanuma M, Miyazaki I, et al. Protective effects of interferon-gamma against methamphetamine-induced neurotoxicity. Toxicol Lett 2008; 177: 123-9.
81. O'Shea E, Sanchez V, Orio L, Escobedo I, Green AR, Colado MI. 3,4-Methylenedioxymethamphetamine increases pro-interleukin-1beta production and caspase-1 protease activity in frontal cortex, but not in hypothalamus, of Dark Agouti rats: role of interleukin-1beta in neurotoxicity. Neuroscience 2005; 135: 1095-105.
82. Orio L, Llopis N, Torres E, Izco M, O'Shea E, Colado MI. A study on the mechanisms by wich minocycline protects against MDMA ('ecstasy')-induced neurotoxicity of 5-HT cortical neurons. Neurotox Res 2010; 18: 187-99.
83. Torres E, Gutierrez-Lopez MD, Borcel E, et al. Evidence that MDMA ('ecstasy') increases CB2 receptor expression in microglial cells: role in the neuroinflammation response in rat brain. J Neurochem 2010; 113: 67-78.
84. Connor TJ. Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): a stressor on the immune system. Immunology 2004; 111: 357-67.
85. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004; 63: 901-10.
86. Kita T, Shimada K, Mastunari Y, Wagner GC, Kubo K, Nakashima T. Methamphetamine-induced striatal dopamine neurotoxicity and cyclooxygenase-2 protein expression in BALB/c mice. Neuropharmacology 2000; 39: 399-406.
87. Thomas DM, Kuhn DM. Cyclooxygenase-2 is an obligatory factor in methamphetamine-induced neurotoxicity. J Pharmacol Exp Ther 2005; 313: 870-6.
88. Zhang X, Dong F, Mayer GE, Bruch DC, Ren J, Culver B. Selective inhibition of cyclooxygenase-2 exacerbates methamphetamine-induced dopamine depletion in the striatum in rats. Neuroscience 2007; 150: 950-8.
89. Asanuma M, Tsuji T, Miyazaki I, Miyoshi K, Ogawa N. Methamphetamine-induced neurotoxicity in mouse brain is attenuated by ketoprofen, a non-steroidal anti-inflammatory drug. Neurosci Lett 2003; 352: 13-6.
90. Tsuji T, Asanuma M, Miyazaki I, Miyoshi K, Ogawa N. Reduction of nuclear peroxisome proliferator-activated receptor gamma expression in methamphetamine-induced neurotoxicity and neuroprotective effects of ibuprofen. Neurochem Res 2009; 34: 764-74.
91. Zhang L, Kitaichi K, Fujimoto Y, et al. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1381-93.
92. Zhang L, Shirayama Y, Shimizu E, Iyo M, Hashimoto K. Protective effects of minocycline on 3,4-methylenedioxymethamphetamine-induced neurotoxicity in serotonergic and dopaminergic neurons of mouse brain. Eur J Pharmacol 2006; 544: 1-9.
93. Prickaerts J, Koopmans G, Blokland A, Scheepens A. Learning and adult neurogenesis: survival with or without proliferation? Neurobiol Learn Mem 2004; 81: 1-11.
94. Lledo PM, Alonso M, Grubb MS. Adult neurogenesis and functional plasticity in neuronal circuits. Nat Rev Neurosci 2006; 7: 179-93.
95. Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. Cell 2008; 132: 645-60.
96. Ehninger D, Kempermann G. Neurogenesis in the adult hippocampus. Cell Tissue Res 2008; 331: 243-50.
97. Chojnacki AK, Mak GK, Weiss S. Identity crisis for adult periventricular neural stem cells: subventricular zone astrocytes, ependymal cells or both? Nat Rev Neurosci 2009; 10: 153-63.
98. Toni N, Laplagne DA, Zhao C, et al. Neurons born in the adult dentate gyrus form functional synapses with target cells. Nat Neurosci 2008; 11: 901-7.
99. Kuhn HG, Dickinson-Anson H, Gage FH. Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. J Neurosci 1996; 16: 2027-33.
100. Kempermann G, Kuhn HG, Gage FH. Experience-induced neurogenesis in the senescent dentate gyrus. J Neurosci 1998; 18: 3206-12.
101. Rao MS, Hattiangady B, Abdel-Rahman A, Stanley DP, Shett, AK. Newly born cells in the ageing dentate gyrus display normal migration, survival and neuronal fate choice but endure retarded early maturation. Eur J Neurosci 2005; 21: 464-76.
102. Gould E, Tanapat P. Stress and hippocampal neurogenesis. Biol Psychiatry 1999; 4: 1472-9.
103. Yu IT, Lee SH, Lee YS, Son H. Differential effects of corticosterone and dexamethasone on hippocampal neurogenesis in vitro. Biochem Biophys Res Commun 2004; 30: 484-90.
104. Nichols NR, Zieba M, Bye N. Do glucocorticoids contribute to brain aging? Brain Res Brain Res Rev 2001; 37: 273-86.
105. Cameron HA, McKay RD. Restoring production of hippocampal neurons in old age. Nat Neurosci 1999; 2: 894-7.
106. Bremner JD. Neuroimaging studies in post-traumatic stress disorder. Curr Psychiatry Rep 2002; 4: 254-63.
107. Czéh B, Simon M, Schmelting B, Hiemke C, Fuchs E. Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsychopharmacology 2006; 31: 1616-26.
108. Mineur YS, Belzung C, Crusio WE. Functional implications of decreases in neurogenesis following chronic mild stress in mice. Neuroscience 2007; 150: 251-9.
109. Banasr M, Hery M, Printemps R, Daszuta A. Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology 2004; 29: 450-60.
110. Encinas JM, Vaahtokari A, Enikolopov G. Fluoxetine targets early progenitor cells in the adult brain. Proc Natl Acad Sci USA 2006; 103: 8233-8.
111. Ekdahl CT, Kokaia Z, Lindvall O. Brain inflammation and adult neurogenesis: the dual role of microglia. Neuroscience 2009; 158: 1021-9.
112. Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci USA 2003; 100: 13632-7.
113. Graciarena M, Depino AM, Pitossi FJ. Prenatal inflammation impairs adult neurogenesis and memory related behavior through persistent hippocampal TGFbeta1 downregulation. Brain Behav Immun 2010; 24: 1301-9.
114. Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003; 302: 1760-5.
115. Bernardino L, Xapelli S, Silva AP, et al. Modulator effects of interleukin-1beta and tumor necrosis factor-alpha on AMPAinduced excitotoxicity in mouse organotypic hippocampal slice cultures. J Neurosci 2005; 25: 6734-44.
116. Bernardino L, Agasse F, Silva B, Ferreira R, Grade S, Malva JO. Tumor necrosis factor-alpha modulates survival, proliferation, and neuronal differentiation in neonatal subventricular zone cell cultures. Stem Cells 2008; 26: 2361-71.
117. Battista D, Ferrari CC, Gage FH, Pitossi FJ. Neurogenic niche modulation by activated microglia: transforming growth factor beta increases neurogenesis in the adult dentate gyrus. Eur J Neurosci 2006; 23: 83-93.
118. Snyder JS, Hong NS, McDonald RJ, Wojtowicz JM. A role for adult neurogenesis in spatial long-term memory. Neuroscience 2005; 130: 843-52.
119. Bruel-Jungerman E, Rampon C, Laroche S. Adult hippocampal neurogenesis, synaptic plasticity and memory: facts and hypotheses. Rev Neurosci 2007; 18: 93-114.
120. Jessberger S, Clark RE, Broadbent NJ, et al. Dentate gyrus-specific knockdown of adult neurogenesis impairs spatial and object recognition memory in adult rats. Learn Mem 2009; 16: 147-54.
121. Brown J, Cooper-Kuhn CM, Kempermann G, et al. Enriched environment and physical activity stimulate hippocampal but not olfactory bulb neurogenesis. Eur J Neurosci 2003; 17: 2042-6.
122. Bednarczyk MR, Aumont A, Décary S, Bergeron R, Fernandes KJ. Prolonged voluntary wheel-running stimulates neural precursors in the hippocampus and forebrain of adult CD1 mice. Hippocampus 2009; 19: 913-27.
123. Llorens-Martín M, Torres-Alemán I, Trejo JL. Growth factors as mediators of exercise actions on the brain. Neuromolecular Med 2008; 10: 99-107.
124. Teuchert-Noodt G, Dawirs RR, Hildebrandt K. Adult treatment with methamphetamine transiently decreases dentate granule cell proliferation in the gerbil hippocampus. J Neural Transm 2000; 107: 133-43.
125. Mandyam CD, Wee S, Crawford EF, Eisch AJ, Richardson HN, Koob GF. Varied access to intravenous methamphetamine selfadministration differentially alters adult hippocampal neurogenesis. Biol Psychiatry 2008; 64: 958-65.
126. Maeda K, Sugino H, Hirose T, et al. Clozapine prevents a decrease in neurogenesis in mice repeatedly treated with phencyclidine. J Pharmacol Sci 2007; 103: 299-308.
127. Kochman LJ, Fornal CA, Jacobs BL. Suppression of hippocampal cell proliferation by short-term stimulant drug administration in adult rats. Eur J Neurosci 2009; 29: 2157-65.
128. Tian C, Murrin LC, Zheng JC. Mitochondrial fragmentation is involved in methamphetamine-induced cell death in rat hippocampal neural progenitor cells. PLoS One 2009; 4: e5546.
129. Höglinger GU, Rizk P, Muriel MP, et al. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 2004; 7: 726-35.
130. Hiramoto T, Kanda Y, Satoh Y, Takishima K, Watanabe Y. Dopamine D2 receptor stimulation promotes the proliferation of neural progenitor cells in adult mouse hippocampus. Neuroreport 2007; 18: 659-64.
131. Dawirs RR, Hildebrandt K, Teuchert-Noodt G. Adult treatment with haloperidol increases dentate granule cell proliferation in the gerbil hippocampus. J Neural Transm 1998; 105: 317-27.
132. Esposito MS, Piatti VC, Laplagne DA, et al. Neuronal differentiation in the adult hippocampus recapitulates embryonic development. J Neurosci 2005; 25: 10074-86.
133. Cameron HA, McEwen BS, Gould E. Regulation of adult neurogenesis by excitatory input and NMDA receptor activation in the dentate gyrus. J Neurosci 1995; 15: 4687-92.
134. Bai F, Bergeron M, Nelson DL. Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus. Neuropharmacology 2003; 44: 1013-21.
135. Nacher J, McEwen BS. The role of N-methyl-D-asparate receptors in neurogenesis. Hippocampus 2006; 16: 267-70.
136. Brazel CY, Nuñez JL, Yang Z, Levison SW. Glutamate enhances survival and proliferation of neural progenitors derived from the subventricular zone. Neuroscience 2005; 131: 55-65.
137. Ge S, Pradhan DA, Ming GL, Song H. GABA sets the tempo for activity-dependent adult neurogenesis. Trends Neurosci 2007; 30: 1-8.
138. Ge S, Sailor KA, Ming GL, Song H. Synaptic integration and plasticity of new neurons in the adult hippocampus. J Physiol 2008; 586: 3759-65.
139. Nguyen L, Malgrange B, Breuskin I, et al. Autocrine/paracrine activation of the GABA(A) receptor inhibits the proliferation of neurogenic polysialylated neural cell adhesion molecule-positive (PSA-NCAM+) precursor cells from postnatal striatum. J Neurosci 2003; 23: 3278-94.
140. Liu X, Wang Q, Haydar TF, Bordey A. Nonsynaptic GABA signaling in postnatal subventricular zone controls proliferation of GFAP-expressing progenitors. Nat Neurosci 2005; 8: 1179-87.
141. Bolteus AJ, Bordey A. GABA release and uptake regulate neuronal precursor migration in the postnatal subventricular zone. J Neurosci 2004; 24: 7623-31.
142. Heck N, Kilb W, Reiprich P, et al. GABA-A receptors regulate neocortical neuronal migration in vitro and in vivo. Cereb Cortex 2007; 17: 138-48.
143. Cho KO, Rhee GS, Kwack SJ, Chung SY, Kim SY. Developmental exposure to 3,4-methylenedioxymethamphetamine results in downregulation of neurogenesis in the adult mouse hippocampus. Neuroscience 2008; 154: 1034-41.
144. Hernández-Rabaza V, Domínguez-Escribà L, Barcia JA, et al. Binge administration of 3,4-methylenedioxymethamphetamine (ecstasy) impairs the survival of neural precursors in adult rat dentate gyrus. Neuropharmacology 2006; 51: 967-73.
145. McCardle K, Luebbers S, Carter JD, Croft RJ, Stough C. Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology (Berl) 2004; 173: 434-9.
146. Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7: 41-53.
147. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 2004; 16: 1-13.
148. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005; 57: 173-85.
149. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 2006; 1: 223-36.
150. Romero IA, Radewicz K, Jubin E, et al. Changes in cytoskeletal and tight junctional proteins correlate with decreased permeability induced by dexamethasone in cultured rat brain endothelial cells. Neurosci Lett 2003; 344: 112-6.
151. Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev 2004; 84: 869-901.
152. Williams KC, Ulvestad E, Hickey WF. Immunology of multiple sclerosis. Clin Neurosci 1994; 2: 229-45.
153. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003; 4: 399-415.
154. Tunkel AR, Scheld WM. Pathogenesis and pathophysiology of bacterial meningitis. Annu Rev Med 1993; 44: 103-20.
155. Carvey PM, Zhao CH, Hendey B, et al. 6-Hydroxydopamineinduced alterations in blood-brain barrier permeability. Eur J Neurosci 2005; 22: 1158-68.
156. Droździk M, Białecka M, Myśliwiec K, Honczarenko K, Stankiewicz J, Sych Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 2003; 13: 259-63.
157. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005; 28: 202-8.
158. Dickstein DL, Biron KE, Ujiie M, Pfeifer CG, Jeffries AR, Jefferies WA. Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease. FASEB J 2006; 20: 426-33.
159. Kanmogne GD, Schall K, Leibhart J, Knipe B, Gendelman HE, Persidsky Y. HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: implication for viral neuropathogenesis. J Cereb Blood Flow Metab 2007; 27: 123-34.
160. Sharma HS, Ali SF. Alterations in blood-brain barrier function by morphine and methamphetamine. Ann N Y Acad Sci 2006; 1074: 198-224.
161. Scott JC, Woods SP, Matt GE, et al. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 2007; 17: 275-97.
162. Bowyer JF, Robinson B, Ali S, Schmued LC. Neurotoxic-related changes in tyrosine hydroxylase, microglia, myelin, and the bloodbrain barrier in the caudate-putamen from acute methamphetamine exposure. Synapse 2008; 62: 193-204.
163. Bowyer JF, Ali S. High doses of methamphetamine that cause disruption of the blood-brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus. Synapse 2006; 60: 521-32.
164. Kiyatkin EA, Brown PL, Sharma HS. Brain edema and breakdown of the blood-brain barrier during methamphetamine intoxication: critical role of brain hyperthermia. Eur J Neurosci 2007; 26: 1242-53.
165. Seiden LS, Sabol KE. Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. NIDA Res Monogr 1996; 163: 251-76.
166. Cadet JL, Thiriet N, Jayanthi S. Involvement of free radicals in MDMA-induced neurotoxicity in mice. Ann Med Interne (Paris) 2001; 152 Suppl 3:IS57-59.
167. Yoshida K, Morimoto A, Makisumi T, Murakami N. Cardiovascular, thermal and behavioral sensitization to methamphetamine in freely moving rats. J Pharmacol Exp Ther 1993; 267: 1538-43.
168. Arora H, Owens SM, Gentry WB. Intravenous (+)-methamphetamine causes complex dose-dependent physiologic changes in awake rats. Eur J Pharmacol 2001; 42: 81-7.
169. Ramirez SH, Potula R, Fan S, et al. Methamphetamine disrupts blood-brain barrier function by induction of oxidative stress in brain endothelial cells. J Cereb Blood Flow Metab 2009; 29: 1933-45.
170. Bai F, Jones DC, Lau SS, Monks TJ. Serotonergic neurotoxicity of 3,4-(+/-)-methylenedioxyamphetamine and 3,4-(+/-)-methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of gamma-glutamyl transpeptidase. Chem Res Toxicol 2001; 14: 863-70.
171. Sharma HS, Ali SF. Acute administration of 3,4-methylenedioxymethamphetamine induces profound hyperthermia, bloodbrain barrier disruption, brain edema formation, and cell injury. Ann N Y Acad Sci 2008; 1139: 242-58.
172. Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 2005; 6: 931-44.
173. Jian Liu K, Rosenberg GA. Matrix metalloproteinases and free radicals in cerebral ischemia. Free Radic Biol Med 2005; 39: 71-80.
174. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia 2002; 39: 279-91.
175. Agrawal SM, Lau L, Yong VW. MMPs in the central nervous system: where the good guys go bad. Semin Cell Dev Biol 2008; 19: 42-51.
176. Fujimura M, Gasche Y, Morita-Fujimura Y, Massengale J, Kawase M, Chan PH. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res 1999; 842: 92-100.
177. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007; 27: 697-709.
178. Avolio C, Ruggieri M, Giuliani F, et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 2003; 136: 46-53.
179. Yong VW, Zabad RK, Agrawal S, Goncalves Dasilva A, Metz LM. Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J Neurol Sci 2007; 259: 79-84.
180. Liuzzi GM, Mastroianni CM, Santacroce MP, et al. Increased activity of matrix metalloproteinases in the cerebrospinal fluid of patients with HIV-associated neurological diseases. J Neurovirol 2000; 6: 156-63.
181. Mastroianni CM, Liuzzi GM. Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies. Trends Mol Med 2007; 13: 449-59.
182. Keogh B, Sheahan BJ, Atkins GJ, Mills KH. Inhibition of matrix metalloproteinases ameliorates blood-brain barrier disruption and neuropathological lesions caused by avirulent Semliki Forest virus infection. Vet Immunol Immunopathol 2003; 94: 185-90.
183. Lohmann C, Krischke M, Wegener J, Galla HJ. Tyrosine phosphatase inhibition induces loss of blood-brain barrier integrity by matrix metalloproteinase-dependent and -independent pathways. Brain Res 2004; 995: 184-96.
184. Wachtel M, Frei K, Ehler E, Fontana A, Winterhalter K, Gloor SM. Occludin proteolysis and increased permeability in endothelial cells through tyrosine phosphatase inhibition. J Cell Sci 1999; 112: 4347-56.
185. Bojarski C, Weiske J, Schöneberg T, et al. The specific fates of tight junction proteins in apoptotic epithelial cells. J Cell Sci 2004; 117: 2097-107.
186. Gurney KJ, Estrada EY, Rosenberg GA. Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiol Dis 2006; 23: 87-96.
187. Mizoguchi H, Yamada K, Mouri A, et al. Role of matrix metalloproteinase and tissue inhibitor of MMP in methamphetamine-induced behavioral sensitization and reward: implications for dopamine receptor down-regulation and dopamine release. J Neurochem 2007; 102: 1548-60.
188. Rawson RA, Washton A, Domier CP, Reiber C. Drugs and sexual effects: role of drug type and gender. J Subst Abuse Treat 2002; 22: 103-8.
189. Joint United Nations Programme on HIV/AIDS, World Health Organization. AIDS Epidemic Update Report 2009; 1-100.
190. Bell JE, Arango JC, Anthony IC. Neurobiology of multiple insults: HIV-1-associated brain disorders in those who use illicit drugs. J Neuroimmune Pharmacol 2006; 1: 182-91.
191. Colfax G, Guzman R. Club drugs and HIV infection: a review. Clin Infect Dis 2006; 42: 1463-9.
192. Toborek M, Lee YW, Flora G, et al. Mechanisms of the bloodbrain barrier disruption in HIV-1 infection. Cell Mol Neurobiol 2005; 25: 181-99.
193. Weeks BS, Lieberman DM, Johnson B, et al. Neurotoxicity of the human immunodeficiency virus type 1 tat transactivator to PC12 cells requires the Tat amino acid 49-58 basic domain. J Neurosci Res 1995; 42: 34-40.
194. Pu H, Hayashi K, Andras IE, Eum SY, Hennig B, Toborek M. Limited role of COX-2 in HIV Tat-induced alterations of tight junction protein expression and disruption of the blood-brain barrier. Brain Res 2007; 1184: 333-44.
195. Mahajan SD, Aalinkeel R, Sykes DE, et al. Tight junction regulation by morphine and HIV-1 tat modulates blood-brain barrier permeability. J Clin Immunol 2008; 28: 528-41.
196. Flora G, Lee YW, Nath A, Hennig B, Maragos W, Toborek M. Methamphetamine potentiates HIV-1 Tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain. Exp Neurol 2003; 179: 60-70.
197. Banks WA, Akerstrom V, Kastin AJ. Adsorptive endocytosis mediates the passage of HIV-1 across the blood-brain barrier: evidence for a post-internalization coreceptor. J Cell Sci 1998; 111: 533-40.
198. Nakamuta S, Endo H, Higashi Y, et al. Human immunodeficiency virus type 1 gp120-mediated disruption of tight junction proteins by induction of proteasome-mediated degradation of zonula occludens-1 and -2 in human brain microvascular endothelial cells. J Neurovirol 2008; 14: 186-95.
199. Mahajan SD, Aalinkeel R, Sykes DE, et al. Methamphetamine alters blood brain barrier permeability via the modulation of tight junction expression: Implication for HIV-1 neuropathogenesis in the context of drug abuse. Brain Res 2008; 1203: 133-48.
200. Banerjee A, Zhang X, Manda KR, Banks WA, Ercal N. HIV proteins (gp120 and Tat) and methamphetamine in oxidative stressinduced damage in the brain: potential role of the thiol antioxidant N-acetylcysteine amide. Free Radic Biol Med 2010; 48: 1388-98.
201. Palmer TD, Willhoite AR, Gage FH. Vascular niche for adult hippocampal neurogenesis. J Comp Neurol 2000; 425: 479-94.
202. Shen Q, Wang Y, Kokovay E, et al. Adult SVZ stem cells lie in a vascular niche: a quantitative analysis of niche cell-cell interactions. Cell Stem Cell 2008; 3: 289-300.
203. Tavazoie M, Van der Veken L, Silva-Vargas V, et al. A specialized vascular niche for adult neural stem cells. Cell Stem Cell 2008; 3: 279-88.
204. Charrier C, Coronas V, Fombonne J, et al. Characterization of neural stem cells in the dorsal vagal complex of adult rat by in vivo proliferation labeling and in vitro neurosphere assay. Neuroscience 2006; 138: 5-16.
205. Kish SJ. Pharmacologic mechanisms of crystal meth. CMAJ 2008; 178: 1679-82.
206. Bellavance MA, Blanchette M, Fortin D. Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J 2008; 10: 166-77.
207. Kast RE. Use of FDA approved methamphetamine to allow adjunctive use of methylnaltrexone to mediate core anti-growth factor signaling effects in glioblastoma. J Neurooncol 2009; 94: 163-7.
208. Kast RE, Focosi D. Three paths to better tyrosine kinase inhibition behind the blood-brain barrier in treating chronic myelogenous leukemia and glioblastoma with imatinib. Transl Oncol 2010; 3: 13-5.